Comparative Pharmacology
Head-to-head clinical analysis: BENICAR HCT versus DIULO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENICAR HCT versus DIULO.
BENICAR HCT vs DIULO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of an angiotensin II receptor blocker (ARB) and a thiazide diuretic. Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
Inhibits the Na+/Cl- symporter in the distal convoluted tubule of the nephron, reducing reabsorption of sodium and chloride, leading to increased diuresis and decreased extracellular fluid volume.
One tablet orally once daily. Available strengths: 40 mg olmesartan / 12.5 mg hydrochlorothiazide, 40 mg olmesartan / 25 mg hydrochlorothiazide. Dose may be titrated after 2-4 weeks based on response.
2.5 mg orally once daily, may increase to 5 mg once daily after 4 weeks if needed.
None Documented
None Documented
Olmesartan: Terminal elimination half-life is 10-15 hours, supporting once-daily dosing. Hydrochlorothiazide: Terminal half-life is 5.6-14.8 hours (mean ~10 hours), prolonged in renal impairment.
Terminal elimination half-life is 1.5-2 hours (mean 1.8 h) in healthy adults; prolonged to 3-6 hours in renal impairment and up to 8 hours in severe heart failure.
Olmesartan: Approximately 50-65% of absorbed dose excreted in urine (10-20% as unchanged drug, remainder as metabolites), 35-50% in feces via biliary excretion. Hydrochlorothiazide: ≥95% excreted renally as unchanged drug.
Primarily renal excretion (60-70% as unchanged drug) via glomerular filtration and tubular secretion; approximately 10-15% biliary/fecal elimination.
Category C
Category C
ARB + Thiazide Diuretic
Thiazide Diuretic